86 results about "STAT6" patented technology

Provided in the present invention are an oxamide compound having a structure as shown in formula (I), or a pharmaceutically acceptable salt, isotope derivative or solvate thereof, or a stereoisomer, geometric isomer or tautomer thereof, or a prodrug molecule or metabolite thereof, and a pharmaceutical composition thereof and the use thereof. The compound involved in the present invention can efficiently inhibit STAT6 phosphorylation, can be used for preparing drugs for preventing and treating inflammatory diseases, and can be used for preparing anti-tumor drugs.

Provided herein are novel compounds, for example, compounds having a Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in modulating the activity of one or more STAT proteins, particularly STAT3 and / or STAT6, and / or in treating various diseases such as cancer.

A compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof in preparation of a drug for preventing or treating STAT6-mediated diseases.

Provided herein are inhibitors of the TFPJ2-CD51-STAT6 signaling axis and methods for the treatment of cancer (e.g., glioblastoma) therewith. In particular, inhibitors of expression or activity of components of the TFPJ2-CD51-STAT6 signaling axis are provided, with or without an immune checkpoint inhibitor, for the treatment of glioblastoma.

The present disclosure relates to extracellular vesicles. e.g., exosomes, comprising an antisense oligonucleotide (ASO), wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a STAT6 transcript. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and / or prevent diseases or disorders.

The invention belongs to the technical field of gene engineering and protein engineering, and particularly relates to a fully human antagonistic antibody taking a lactylated STAT6 protein as a target spot and application of the fully human antagonistic antibody. According to the present invention, the completely humanized antagonistic antibody using the lactylated STAT6 protein as the target spot is screened from the human scFv phage antibody library, the amino acid sequence of the completely humanized antagonistic antibody is represented by SEQ ID NO: 1, and the completely humanized antagonistic antibody has the specificity of the targeted lactylated STAT6 protein, and has the application prospect in preparation of the product for diagnosis, treatment or alleviation of sepsis immunosuppression.

The invention relates to the technical field of medicines, in particular to an STAT6 inhibitor, a preparation method of the STAT6 inhibitor and application of the STAT6 inhibitor in medicines. The invention provides an oxamide compound with a structure shown in a formula (III) or pharmaceutically acceptable salt, an isotope derivative and a solvate thereof, or a stereoisomer, a geometric isomer and a tautomer thereof, or a prodrug molecule and a metabolite thereof, as well as a medicinal composition and application of the oxamide compound, the salt, the isotope derivative and the solvate of the oxamide compound, the stereoisomer, the geometric isomer and the tautomer thereof, the prodrug molecule and the metabolite of the oxamide compound. The compounds may be used to treat or prevent STAT6 mediated diseases or disorders and related diseases or disorders.

The invention provides a small molecule compound for targeted degradation of STAT6 protein, a preparation method of the small molecule compound and application of the small molecule compound in prevention and / or treatment of immune diseases, inflammatory diseases and cancers. The compound can effectively degrade and / or inhibit STAT6 protein in cells, and can be used for preparing drugs for treating and / or preventing related diseases or symptoms caused by STAT6 mediation.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The present disclosure relates to compounds and methods useful for the modulation of signal transducer and activator of transcription 6 ("STAT6") via ubiquitination and / or degradation by compounds according to the present disclosure. The present disclosure also provides pharmaceutically acceptable compositions thereof and methods of using said compositions in the treatment of various disorders.

Modulators of signal transducer and activator of transcription 6 (STAT6) are provided, including compounds of Formula I, la, lb, Ic, Id, II, Ila, lib, and lie, pharmaceutical compositions thereof, and methods of treating an inflammatory condition or disease.

The invention relates to an STAT6 selective degradation agent compound shown in a formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the STAT6 selective degradation agent compound or the stereoisomer or the pharmaceutically acceptable salt thereof, and application of the STAT6 selective degradation agent compound or the stereoisomer or the pharmaceutically acceptable salt in preparation of drugs for preventing or treating STAT6-mediated diseases.

The invention provides a nitrogen-containing heterocyclic ring compound with a structure as shown in a formula (I), or pharmaceutically acceptable salt, isotope derivative and solvate thereof, or stereoisomer, geometric isomer and tautomer thereof, or prodrug molecule and metabolite thereof, as well as a medicinal composition and application of the nitrogen-containing heterocyclic ring compound. The compound provided by the invention can efficiently inhibit STAT6 phosphorylation, can be used for preparing drugs for preventing and treating inflammatory diseases, and can also be used for preparing antitumor drugs.

Compositions of matter and therapeutic methods for preventing, reducing, or reversing liver pathologies. Autologous pluripotent stem cells for generating monocytes or macrophages that are capable of suppressing liver failure. Methods of administering monocytes that are engineered or induced to facilitate hepatic regeneration. Hepatogenic cells such as monocytes are generated from induced pluripotent stem cells. Hepatogenic cells can be generated by overexpression of one or a plurality of factors associated with an M2 phenotype in pluripotent stem cell-derived monocytes such as signal transducer and activator of transcription 6 (STAT6) and transforming growth factor-beta. Hepatogenic monocytes can be generated in an environment that simulates liver injury.

The invention relates to the technical field of biology, and particularly provides an immortalized cell line of a central nervous system isolated fibroid tumor (CNS SFT). The cell line is constructed through human telomerase reverse transcriptase (hTERT)-mediated lentivirus infection after primary culture of human CNS SFT tumor tissues, has stable and infinite proliferation capability, can be passaged in vitro for more than 20 generations, and keeps the characteristics of tumor cells. The cell strain expresses a feature fusion gene NAB2-STAT6 of the CNS SFT, and the feature fusion gene NAB2-STAT6 is determined to be from a CNS SFT tumor through identification. The cell strain is named as TT-SFT-6569 and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 1, 2025, and the preservation number of the cell strain is CGMCC No.46559. The invention further discloses a preparation method of the cell strain. The cell line can be used as a CNS SFT in-vitro model, is used for screening of candidate drugs and research of a neogenesis mechanism, and provides an important tool for drug development and pathological research of CNS SFT.

The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein the variable are as defined herein. The invention further provides modulators or inhibitors of STAT6 activity, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-4 and / or IL-13.

The invention discloses application of an inhibitor Acevaltrate targeting PCBP2 in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The invention discloses application of PCBP2 as a molecular target of a drug for treating allergic asthma. The core pathological mechanism of allergic asthma is closely related to M2 polarization of macrophages, and PCBP2 positively drives the polarization process by regulating an STAT6 signal channel. Acevaltrate can specifically inhibit the biological function of PCBP2 and block M2 polarization of macrophages induced by IL-4 / IL-13, so that airway inflammation is relieved, over-generation of IgE (immunoglobulin E) is inhibited, and airway remodeling is improved. The invention further provides a pharmaceutical composition containing the Acevaltrate, a drug combination scheme of the Acevaltrate and an existing asthma treatment drug, and a drug screening system based on a PCBP2-M2 polarization axis. The technology breaks through the limitation of an existing asthma treatment target spot, realizes the trans-boundary application of Acevaltrate from an anti-tumor drug to an anti-asthma drug, provides an accurate and efficient novel treatment strategy for allergic asthma, especially refractory asthma, and has remarkable clinical transformation value and wide application prospects.